Loading
Life sciences · Journal article
Cancer Immunology Immunotherapy · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Effective immunotherapeutic strategies for high-grade serous ovarian cancer (HGSOC) remain limited despite evidence of tumor immunogenicity. Here, we report the longitudinal immune characterization of a patient with homologous recombination-deficient HGSOC treated with a personalized neoantigen-based dendritic cell (DC) vaccine during maintenance therapy with the PARP inhibitor olaparib. Following neoadjuvant chemotherapy and interval debulking surgery, the patient in complete response received an autologous monocyte-derived DC vaccine loaded with seven synthetic patient-specific neoantigen peptides (PEP-DC). The vaccine was well tolerated, with no serious vaccine-related adverse events. Comprehensive immune monitoring using flow cytometry, IFN- γ ELISpot assays, and bulk and single-cell T-cell receptor (TCR) sequencing revealed durable induction of neoantigen-specific immune responses, including polyfunctional T-cell responses and expansion of both de novo and pre-existing vaccine-related T-cell clonotypes. By integrating longitudinal TCR repertoire profiling with functional validation assays, we identified one vaccine-specific CD4 TCR and two CD8 TCRs recognizing tumor neoantigens. This proof-of-concept study demonstrates that personalized neoantigen vaccination can induce durable and diverse tumor-specific T-cell responses in ovarian cancer and establishes a framework for using vaccination as an in vivo platform to identify clinically relevant tumor-specific TCRs for future cellular therapies.